Background & Aims
Abbreviations used in this paper:BG (blood glucose), EAG (estimated average glucose), END-PAC (Enriching New-Onset Diabetes for Pancreatic Cancer), EXPAND (Examination of the Pancreas in New-Onset Diabetes), FBG (fasting blood glucose), NOD (new-onset diabetes), PC (pancreatic cancer), PC-NOD (pancreatic cancer in new-onset diabetes), REP (Rochester Epidemiology Project), T2-NOD (type 2 new-onset diabetes)
- Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res. 2014; 74: 2913-2921
- Probability of pancreatic cancer following diabetes: a population-based study.Gastroenterology. 2005; 129: 504-511
SEER. Fast facts: pancreatic cancer. Available at: http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed January 17, 2018.
- Detecting early pancreatic cancer: problems and prospects.Semin Oncol. 2007; 34: 284-294
- A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus.Cancer. 2002; 94: 2344-2349
- Should pancreas imaging be recommended in patients over 50 years when diabetes is discovered because of acute symptoms?.Diabetes Metab. 2004; 30: 203-207
- New-onset type 2 diabetes mellitus—a high-risk group suitable for the screening of pancreatic cancer?.Pancreatology. 2016; 16: 266-271
- Predictors for pancreatic cancer diagnosis following new-onset diabetes mellitus.Clin Transl Gastroenterol. 2015; 6: e118
- A clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.Gastroenterology. 2017; 152: 840-850.e3
- New-onset diabetes and pancreatic cancer.Clin Gastroenterol Hepatol. 2006; 4: 1366-1372
- New-onset diabetes in pancreatic cancer: a study in the primary care setting.Pancreatology. 2012; 12: 156-161
- Delay in diagnosis of diabetes is not the patient’s fault.Diabetes Care. 2010; 33: e10
- Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis.Diabetes Care. 1992; 15: 815-819
- Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence.Diabetes Care. 2014; 37: 1668-1674
- Weight change and diabetes incidence: findings from a national cohort of US adults.Am J Epidemiol. 1997; 146: 214-222
- New insights into pancreatic cancer-induced paraneoplastic diabetes.Nat Rev Gastroenterol Hepatol. 2013; 10: 423-433
- Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus.Pancreas. 2011; 40: 768-772
- Incidence rate of prediabetes progression to diabetes: modeling an optimum target group for intervention.Popul Health Manag. 2017; 20: 216-223
- Normal fasting plasma glucose and risk of type 2 diabetes diagnosis.Am J Med. 2008; 121: 519-524
- Prevalence and clinical profile of pancreatic cancer–associated diabetes mellitus.Gastroenterology. 2008; 134: 981-987
Centers for Disease Control and Prevention. Available at: https://gis.cdc.gov/grasp/diabetes/diabetesatlas.html. Accessed January 17, 2018.
American Cancer Society. Pancreatic cancer risk factors. Available at: https://www.cancer.org/cancer/pancreatic-cancer/causes-risks-prevention/risk-factors.html. Accessed January 17, 2018.
- History of the Rochester Epidemiology Project.Mayo Clin Proc. 1996; 71: 266-274
- History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.Mayo Clin Proc. 2012; 87: 1202-1213
- Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer.Gastroenterology. 2001; 121: 640-645
- Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice.Gastroenterology. 2012; 143: 1510-1517.e1
- Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer.Am J Gastroenterol. 2009; 104: 2318
- Pancreatic cancer–associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.Gastroenterology. 2008; 134: 95-101
- Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science. 2018; 359: 926-930
- Integrating the predictiveness of a marker with its performance as a classifier.Am J Epidemiol. 2008; 167: 362-368
- Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility?.Clin Chem. 2016; 62: 737-742
- Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis.Gastroenterology. 2018; 155: 490-500
- Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis.Am J Gastroenterol. 2007; 102: 2157-2163
- A cost analysis of a pancreatic cancer screening protocol in high-risk populations.Am J Surg. 2015; 210: 409-416
This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e29. Learning Objective: Upon completion of this CME activity, successful learners will be able to describe the Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) risk prediction model and interpret its scoring/results.
Conflicts of interest The authors disclose no conflicts.
Funding This work was supported by the National Institutes of Health U01 Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic cancer (CPDPC; STC and FZ), the Pancreatic Cancer Action Network (STC and WH), the Kenner Family Research Fund (STC), and the Prokopanko Gift to the Mayo Foundation (STC and GMP; U01DK108328 to FZ; and U24086368 to FZ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any other funding source. This study was made possible by the Rochester Epidemiology Project (grant RO1-AG034676; principal investigators: Walter A. Rocca, MD, MPH, and Jennifer L. St Sauver, PhD).